IPO Preview: ContraFect (CFRX)
Seeking Alpha (registration)
Biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. High price to book, 5.6. High cash burn …
ContraFect Announces Pricing of Its Initial Public OfferingMarketwired (press release)
IPO Report: ContraFect (CFRXU)Equities.com

all 6 news articles